Elvitegravir/cobicistat/emtricitabine/tenofovir

Elvitegravir/cobicistat/emtricitabine/tenofovir, sold under the brand name Stribild, also known as the Quad pill, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. Elvitegravir, emtricitabine and tenofovir disoproxil directly suppress viral reproduction. Cobicistat increases the effectiveness of the combination by inhibiting the liver and gut wall enzymes that metabolize elvitegravir. It is taken by mouth.

This article is about the combination medication elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil. For the combination medication elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, see Tenofovir alafenamide ยง combinations.
Elvitegravir/cobicistat/emtricitabine/tenofovir
Combination of
ElvitegravirIntegrase inhibitor
CobicistatCytochrome P450 inhibitor
EmtricitabineReverse-transcriptase inhibitor
Tenofovir disoproxilReverse-transcriptase inhibitor
Clinical data
Trade namesStribild
AHFS/Drugs.comProfessional Drug Facts
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: WARNINGRx-only
  • EU: Rx-only
Identifiers
CAS Number
ChemSpider
  • none
KEGG

The drug is manufactured by Gilead Sciences.

Serum creatinine (a marker of kidney function) may increase with use of Elvitegravir/cobicistat/emtricitabine/tenofovir. This is caused by cobicistat's inhibition of tubular secretion in the nephron. An increase of up to 0.3 mg/dL is expected; if serum creatinine level increases by 0.4 mg/dL or more, further evaluation for other causes of acute kidney injury is recommended.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.